

Primary outcome and outcome measure reporting in randomized trials evaluating treatments for preeclampsia: a systematic review.

Dr James M. N. Duffy¹, Dr Martin Hirsch^{2,3}, Dr Chris Gale⁴, Dr Louise Pealing¹, Dr Anusuya Kawsar³, Mrs Marian Showell⁵, Prof Paula R. Williamson⁶, Prof Khalid S. Khan², Prof Sue Ziebland¹, NIHR Prof Richard J. McManus¹

On behalf of the International Collaboration to Harmonize Outcomes in Preeclampsia (iHOPE) *steering committee listed at the end of the manuscript.

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

² Women's Health Research Unit, Queen Mary, University of London, London, United Kingdom.

³ Royal Free London NHS Trust, London, United Kingdom.

⁴ Neonatal Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom.

⁵ Cochrane Gynaecology and Fertility Group, University of Auckland, Auckland, New Zealand.

⁶ MRC North West Hub for Trials Methodology Research, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.

Correspondence to:

Dr James M N Duffy MBChB MRes BSc (Hons) PG HCL
Balliol College, University of Oxford, Oxford OX2 6GG, United Kingdom.
+44 (0)1865 289298
james.duffy@balliol.ox.ac.uk

Keywords:

(1) Core outcome sets; (2) Newborn; (3) Outcome reporting bias; (4) Preeclampsia; (5) Randomized controlled trials; and (6) Systematic review.

Synopsis:

Randomized trials evaluating treatments for preeclampsia often omit critical information related to their primary outcome, including definition and measurement. A core outcome set is required.

Word count of the main text:

1,762 words

Abstract

Background: To develop a core outcome set an evaluation of primary outcome and outcome measure reporting is required.

Objectives: To assess primary outcome and outcome measure reporting across randomized trials evaluating treatments for preeclampsia.

Search strategy: We searched Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, MEDLINE, and PsycINFO from inception to January 2016.

Selection criteria: Randomized trials evaluating treatments for preeclampsia.

Data collection and analysis: We systematically extracted and categorized primary outcome and outcome measure reporting.

Main results: Seventy-nine randomized trials, including data from 31,615 maternal participants were included. Thirty-eight trials (48%) reported 35 different primary outcomes, of which 28 were maternal outcomes and seven were offspring outcomes. Three randomized trials reported composite outcomes including between seven and nine outcome components. The method of definition or measurement was infrequently or poorly reported within trial reports. When outcomes were consistently reported across trials, different methods of definition or measurement were frequently described.

Conclusions: Randomized trials evaluating interventions for preeclampsia regularly omit critical information related to their primary outcome, including definition and measurement. Developing a core outcome set for preeclampsia trials should help inform primary outcome and outcome measure selection.

Introduction

Preeclampsia, a pregnancy specific multisystem syndrome, is a common cause of maternal and offspring mortality and morbidity.(1) Interventions capable of reducing this substantial health burden are urgently required. Randomized trials are the best way of establishing the efficacy and safety of new treatments; but are only as credible as their primary outcomes.(2) There is currently no consensus regarding the selection of primary outcomes and methods of definition or measurement for preeclampsia trials.(3) The primary outcome should be the outcome of greatest therapeutic importance to the study's prospective hypothesis.(4) In the absence of a standardized approach, researchers may make arbitrary decisions when selecting between several important outcomes.(5) Within the context of preeclampsia, the requirement to evaluate efficacy and safety within maternal participants and their offspring provides additional complexity. Outcome reporting bias may occur should this selection occur retrospectively based upon statistical significance of the results. (6, 7)

Researchers may need to make pragmatic decisions and select a less informative primary outcome when designing trials, influenced by factors such as sample size requirement, costs, and time.(8) The selection of a composite outcome could increase statistical efficiency because of higher event rates and avoids arbitrary choices between several important outcomes, reflecting the multisystem preeclampsia syndrome.(9) Researchers may be unable to select otherwise appropriate outcomes because of the lack of objective definitions or validated instruments.

The first step in developing a core outcome set for preeclampsia requires an evaluation of primary outcome and outcome measure reporting.⁽³⁾ Therefore, we assessed the consistency of primary outcome reporting, including the adequacy of information pertaining to definition and measurement, across randomized trials evaluating treatments for preeclampsia.

Materials and methods

A protocol with explicitly defined objectives, criteria for study selection, approaches to assessing study quality, and statistical methods was developed. We have reported the systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.⁽¹⁰⁾

A systematic literature review was undertaken searching the Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINHAL), MEDLINE, EMBASE, and PsycINFO, from the inception to January 2016 (Appendix S1). Two authors independently screened each potentially relevant record based on title and abstract then reviewed the full text of each selected study to assess eligibility. Discrepancies between the authors were resolved through discussion.

We included randomized controlled trials evaluating the efficacy of any treatment for preeclampsia. We did not exclude trials in mixed populations of antenatal or postnatal participants. We did not exclude trials in mixed populations of participants with preeclampsia and chronic hypertension and / or gestational hypertension. We

applied no restrictions for languages or publication date and translated two trial reports.

Using a pilot-tested and standardized data extraction form, two authors independently extracted study characteristics including participants, interventions, and outcomes. Discrepancies between authors were resolved through discussion. We did not contact authors to clarify primary outcomes or outcome measures which were unclearly reported.

We developed a comprehensive inventory of primary outcomes. If a primary outcome was not explicitly stated, we extracted the outcome included in the study's power calculation. We initially organized outcomes into two broad categories: maternal and offspring outcomes. We subsequently organized these outcomes into individual domains, in consultation with healthcare professionals, researchers, and patients. We used descriptive statistics to characterize our included trials, mapping primary outcomes and their methods of definition or measurement across included trials.

Results

We discovered 10,720 records, after excluding 3,627 duplicate records, 7,093 titles and abstracts were screened, and 162 potentially relevant studies were examined (Figure 1). Seventy-nine randomized trials, reporting data from 31,615 maternal participants, met our inclusion criteria. Nearly half of included trials (38 trials; 48%) reported a primary outcome.(11-48)

Thirty-five different primary outcomes were reported, of which 28 were maternal outcomes and seven offspring outcomes. These outcomes were organized in consultation with health care professionals, researchers, and patients into 16 domains, including five maternal domains and five offspring domains (Table 1).

Primary maternal outcomes more frequently reported included blood pressure (10 trials; 13%), eclampsia (7 trials; 9%), maternal mortality (3 trials; 4%), and pulmonary edema (3 trials; 4%). Primary offspring outcomes were infrequently reported, for example, Offspring mortality was reported by two trials (3%), neonatal respiratory distress syndrome was reported by a single trial (1%), and a single trial (1%) reported neurological development (Table 1).

Three trials (4%) reported composite outcomes (Table 1). The number of components ranged from seven to nine. Two components, maternal mortality and pulmonary edema, was common to all composite outcomes. Only one trial (1%) included an offspring outcome, neonatal repository distress syndrome, within the composite outcomes. The components of the composite outcome did not change in the three trial reports between the abstract, methods, and results. Six trials (8%) reported more than one primary outcome. Three trials (3%) reported more than one primary maternal outcome (range 2-3 outcomes). A single trial (1%) reported two primary offspring outcomes. Two trials (3%) reported primary maternal and offspring outcomes (range 2-3 outcomes).

Thirty-four different methods of definition or measurement were reported (Table 2). Even when outcomes were consistently reported across included trials, different

methods of definition or measurement were described. For example, blood pressure was reported in three different ways: (1) systolic blood pressure; (2) diastolic blood pressure; (3) mean arterial blood pressure.

Discussion

Randomized trials evaluating interventions for preeclampsia regularly omit information pertaining to primary outcomes and outcome measures. Nearly half of included trials explicitly reported a primary outcome. When primary outcomes were consistently reported across trials, different methods of definition or measurement were frequently described. Such variation contributes to an inability to compare, contrast, and combine individual studies and limits the usefulness of research to inform clinical practice.

The strengths of this systematic review include its originality, comprehensive search strategy, methodological design, and statistical analysis. To our knowledge, this is the first systematic review to map primary outcomes and their means of definition and measurement in preeclampsia trials. To prevent bias in the review process, study selection, and data extraction and assessment were conducted independently by two authors. An international steering group, including women with lived experience of preeclampsia, was formed to oversee the study, their input was central to the development of a comprehensive inventory of primary outcomes.

Our empirical evaluation has limitations. We considered those outcomes which were included within a sample size calculation as a primary outcome. The lack of explicit primary outcome in many trials meant that we occasionally mapped outcomes which

were not recorded as primary outcomes within the trial report. We did not contact authors to clarify primary outcomes or outcome measures which appeared unclear. Primary outcomes, especially in earlier phase efficacy trials, may be chosen to reflect the aim of the intervention. We would not necessarily expect the primary outcome for trials of antihypertensives to be the same as anticonvulsants. Examining primary outcome reporting and its relationship with other factors including year of publication, commercial funding, and journal impact factor could provide additional understanding.(49, 50) However, no validated outcome reporting quality assessment tools currently exist, limiting our ability to undertake this analysis.

The Global Pregnancy CoLaboratory, an international collaboration involving key stakeholders including healthcare professionals, researchers, and women with lived experience of preeclampsia, have published a strategy to standardize preeclampsia research study design including data set standards for research studies.(51) Their work reflects the enthusiasm of the pre-eclampsia research community to work together to improve research design and clinical care. The next challenge is to address poor outcome reporting driving outcome reporting bias by developing and implementing core outcome sets.

The Core Outcomes in Women's and Newborn Health (CROWN) initiative has been formed to tackle the challenge of addressing the unwarranted variation in outcome collection and reporting.(52) Participating journals aim to reduce research waste by facilitating consistent reporting of core outcomes.(53) Core outcome sets are minimum collections of outcomes that are predefined, measured in a standardized manner, and reported consistently in the final publication.(54) The outcomes do not

need to be extensive and researchers remain free to measure and report other outcomes. Ideally the primary outcome and outcome measure should be selected from the core outcome set. The Core Outcome Measures for Efficacy Trials (COMET) initiative advocates the development of core outcome sets by groups including healthcare professionals, researchers, and patients. Their development typical includes three broad stages: (1) identifying potential core outcomes; (2) determining core outcomes using robust consensus methods engaging key stakeholders, and (3) determining how core outcomes should be measured.(8, 54) Several consortiums have been established developing core outcome sets across our specialty.(55-57)

An international steering group, including healthcare professionals, researchers, and patients, has been formed to develop a core outcome set for preeclampsia. The inventory of primary outcomes identified by this systematic review has contributed to the long list of outcomes entered into a modified Delphi method. Consensus 'core' outcomes for pre-eclampsia have been identified by 283 healthcare professionals, 41 researchers, and 112 patients from 55 countries.(58)

In conclusion, randomized trials evaluating interventions for preeclampsia regularly omit information related to the primary outcome and its definition or measurement. Implementing a core outcome set in future preeclampsia trials should help inform primary outcome and outcome measure selection and facilitate consistent reporting.

Author contributions

Study concept and design: JMD, PRW, KSK, SZ, and RMcM. Acquisition of data: JMD, MH, AK, LP, and MS. Analysis and interpretation of data: JMD, MH, CG, PRW, KSK, SZ, and RMcM. Drafting of the manuscript: JMD, CG, KSK, SZ, and RMcM. Critical revision of the manuscript for important intellectual content: MH, AK, CG, LP, MS, and PRW. Obtained funding: JMD, PRW, KSK, SZ, and RMcM. Administrative, technical, or material support: PRW and MS. Educational supervision: PRW KSK, SZ, and RMcM.

Acknowledgements

This report is independent research arising from a doctoral fellowship (DRF-2014-07-051) supported by the National Institute for Health Research. Dr Chris Gale was supported during this study by a National Institute for Health Research Clinical Trials Fellowship (NIHR-CTF-2014-03-02) and a Medical Research Council Clinician Scientist Fellowship (MR/N008405/1). Prof Richard McManus is supported by a National Institute for Health Research Professorship (NIHR-RP-R2-12-015) and the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Oxford. Prof Sue Ziebland is a NIHR Senior Investigator. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.

We would like to thank the Radcliffe Women's Health Patient Participation group, Action on Preeclampsia, and our patient and public representatives who assisted with study design, data interpretation, and planned dissemination. We would like to

thank colleagues at the Nuffield Department of Primary Care Health Sciences, University of Oxford including Carla Betts, Dawn Evans, Caroline Jordan, Sam Monaghan, Dan Richards-Doran, Nicola Small, and Clare Wickings for administrative, technical, and material support. We would like to thank colleagues at the Women's Health Research Unit, Queen Mary, University of London including Tracy Holtham and Rehan Khan for administrative, technical support, and subject-specific expertise. We would like to thank David Mills for administrative and material support.

Conflict of Interest

RM has received blood pressure monitors for research from Omron and Lloyds Pharmacies and expenses and honoraria for speaking from the Japanese Society of Hypertension and the American Society of Nephrology. The remaining authors declare no competing interests.

International Collaboration to Harmonize Outcomes in Preeclampsia (iHOPE) steering group

James M. N. Duffy (University of Oxford, Oxford, United Kingdom); Janneke van 't Hooft (Academical Medical Centre, Amsterdam, Netherlands); Chris Gale (Imperial College London, London, United Kingdom); Mark Brown (St George and Sutherland Hospitals, Kogarah, Australia); William Grobman (Northwestern University, Chicago, United States); Ray Fitzpatrick (University of Oxford, Oxford, United Kingdom); S. Ananth Karumanchi (Harvard Medical School, Boston, United States); Nuala Lucas (Obstetric Anaesthetists' Association, London, United Kingdom); Laura Magee (St George's, University of London, London, United Kingdom); Ben Mol (University of

Adelaide, Adelaide, Australia); Michael Stark (University of Adelaide, Adelaide, Australia); Shakila Thangaratinam (Queen Mary, University of London, London, United Kingdom); Mathew Wilson (University of Sheffield, Sheffield, United Kingdom); Peter von Dadelszen (St George's, University of London, London, United Kingdom); Paula R. Williamson (University of Liverpool, Liverpool, United Kingdom); Khalid S. Khan (Queen Mary, University of London, London, United Kingdom); Sue Ziebland (University of Oxford, Oxford, United Kingdom); and Richard J. McManus (University of Oxford, Oxford, United Kingdom).

References

1. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. *Pregnancy Hypertens.* 2014;4(2):97-104.
2. Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. *Lancet.* 2014;383(9912):166-75.
3. Duffy JMN, van 't Hooft J, Gale C, Brown M, Grobman W, Fitzpatrick R, et al. A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. *Pregnancy Hypertension.* 2016;6(4):274-8.
4. Schulz KF, Altman DG, Moher D, Group C, Altman DG, Barbour V, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Bmj.* 2010;340:c332.

- 315 5. Macefield RC, Boulind CE, Blazeby JM. Selecting and measuring optimal
316 outcomes for randomised controlled trials in surgery. *Langenbecks Arch Surg.*
317 2014;399(3):263-72.
- 318 6. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ.
319 Selective reporting bias of harm outcomes within studies: findings from a cohort of
320 systematic reviews. *Bmj.* 2014;349:g6501.
- 321 7. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable
322 selection within studies. *J Roy Stat Soc C-App.* 2000;49:359-70.
- 323 8. Duffy JMN, McManus RJ. Influence of methodology upon the identification of
324 potential core outcomes. Recommendations for core outcome set developers are
325 needed. *BJOG.* 2016;123(10):1599.
- 326 9. Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition,
327 reporting, and interpretation of composite outcomes in clinical trials: systematic
328 review. *Bmj.* 2010;341:c3920.
- 329 10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al.
330 The PRISMA statement for reporting systematic reviews and meta-analyses of
331 studies that evaluate health care interventions: explanation and elaboration. *J Clin*
332 *Epidemiol.* 2009;62(10):e1-34.
- 333 11. Broekhuijsen K, van Baaren GJ, van Pampus MG, Ganzevoort W, Sikkema
334 JM, Woiski MD, et al. Immediate delivery versus expectant monitoring for
335 hypertensive disorders of pregnancy between 34 and 37 weeks of gestation
336 (HYPITAT-II): an open-label, randomised controlled trial. *Lancet.*
337 2015;385(9986):2492-501.
- 338 12. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam
339 DJ, et al. Induction of labour versus expectant monitoring for gestational

hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. *Lancet*. 2009;374(9694):979-88.

13. Owens MY, Thigpen B, Parrish MR, Keiser SD, Sawardecker S, Wallace K, et al. Management of preeclampsia when diagnosed between 34-37 weeks gestation: deliver now or deliberate until 37 weeks? *J Miss State Med Assoc*. 2014;55(7):208-11.

14. Ascarelli MH, Johnson V, McCreary H, Cushman J, May WL, Martin JN, Jr. Postpartum preeclampsia management with furosemide: a randomized clinical trial. *Obstet Gynecol*. 2005;105(1):29-33.

15. Bolte AC, van Eyck J, Kanhai HH, Bruinse HW, van Geijn HP, Dekker GA. Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. *Am J Obstet Gynecol*. 1999;180(2):371-7.

16. Elatrous S, Nouira S, Ouanes Besbes L, Marghli S, Boussarssar M, Sakkouhi M, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nifedipine and labetalol. *Intensive Care Med*. 2002;28(9):1281-6.

17. Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. *BJOG*. 2000;107(6):759-65.

18. Manzur-Verastegui S, Mandeville PB, Gordillo-Moscoso A, Hernandez-Sierra JF, Rodriguez-Martinez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. *Clin Exp Pharmacol Physiol*. 2008;35(5-6):580-5.

19. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type

364 5 inhibitor sildenafil for the treatment of preeclampsia. *Hypertens Pregnancy*.
365 2009;28(4):369-82.

366 20. Scardo JA, Vermillion ST, Newman RB, Chauhan SP, Hogg BB. A
367 randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in
368 preeclamptic hypertensive emergencies. *Am J Obstet Gynecol*. 1999;181(4):862-6.

369 21. van Schie DL, de Jeu RM, Steyn DW, Odendaal HJ, van Geijn HP. The
370 optimal dosage of ketanserin for patients with severe hypertension in pregnancy. *Eur*
371 *J Obstet Gynecol Reprod Biol*. 2002;102(2):161-6.

372 22. Verma R, Lahon K, Tonpay S, Kale VJ, Jain DK. A comparative randomised
373 controlled parallel group study of efficacy and tolerability of labetalol versus
374 methyldopa in the treatment of new onset hypertension during pregnancy. *Int J Life*
375 *Sci Pharma Res*. 2012;2(1):23-31.

376 23. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, Lopez JC,
377 et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized
378 clinical trial. *Eur J Obstet Gynaecol Reprod Biol*. 2006;128(1-2):157-62.

379 24. Adair CD, Luper A, Rose JC, Russell G, Veille JC, Buckalew VM. The
380 hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe
381 preeclampsia: a double-blind, randomized, clinical trial. *J Perinatol*. 2009;29(4):284-
382 9.

383 25. Adair CD, Buckalew VM, Graves SW, Lam GK, Johnson DD, Saade G, et al.
384 Digoxin immune fab treatment for severe preeclampsia. *Am J Perinatol*.
385 2010;27(8):655-62.

386 26. Belfort MA, Anthony J, Saade GR, Allen JC, Jr. A comparison of magnesium
387 sulfate and nimodipine for the prevention of eclampsia. *N Engl J Med*.
388 2003;348(4):304-11.

- 389 27. Darngawn L, Jose R, Regi A, Bansal R, Jeyaseelan L. A shortened
390 postpartum magnesium sulfate prophylaxis regime in pre-eclamptic women at low
391 risk of eclampsia. *Int J Gynaecol Obstet.* 2012;116(3):237-9.
- 392 28. Dasgupta S, Ghosh D, Seal SL, Kamilya G, Karmakar M, Saha D.
393 Randomized controlled study comparing effect of magnesium sulfate with placebo on
394 fetal umbilical artery and middle cerebral artery blood flow in mild preeclampsia at
395 \geq 34 weeks gestational age. *J Obstet Gynaecol Res.* 2012;38(5):763-71.
- 396 29. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women
397 with eclampsia? Evidence from the Collaborative Eclampsia Trial. *Lancet.*
398 1995;345(8963):1455-63.
- 399 30. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women
400 with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie
401 Trial: a randomised placebo-controlled trial. *Lancet.* 2002;359(9321):1877-90.
- 402 31. Ehrenberg HM, Mercer BM. Abbreviated postpartum magnesium sulfate
403 therapy for women with mild preeclampsia: a randomized controlled trial. *Obstet*
404 *Gynecol.* 2006;108(4):833-8.
- 405 32. Fontenot MT, Lewis DF, Frederick JB, Wang Y, DeFranco EA, Groome LJ, et
406 al. A prospective randomized trial of magnesium sulfate in severe preeclampsia: use
407 of diuresis as a clinical parameter to determine the duration of postpartum therapy.
408 *Am J Obstet Gynecol.* 2005;192(6):1788-93; discussion 93-4.
- 409 33. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium
410 sulfate in women with mild preeclampsia: a randomized controlled trial. *Obstet*
411 *Gynecol.* 2003;101(2):217-20.
- 412 34. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate
413 with phenytoin for the prevention of eclampsia. *N Engl J Med.* 1995;333(4):201-5.

- 414 35. Maia SB, Katz L, Neto CN, Caiado BV, Azevedo AP, Amorim MM.
415 Abbreviated (12-hour) versus traditional (24-hour) postpartum magnesium sulfate
416 therapy in severe pre-eclampsia. *Int J Gynaecol Obstet.* 2014;126(3):260-4.
- 417 36. Walss Rodriguez RJ, Reyes Levario A. Tratamiento anticonvulsivante de la
418 preeclampsia severa. Comparacion entre diazepam y sulfato de magnesio. *Ginecol*
419 *Obstet Mex.* 1992;60:331-5.
- 420 37. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy
421 on the duration of labor in women with mild preeclampsia at term: a randomized,
422 double-blind, placebo-controlled trial. *Am J Obstet Gynecol.* 1997;176(3):623-7.
- 423 38. Gulmezoglu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the treatment
424 of severe pre-eclampsia: an explanatory randomised controlled trial. *BJOG.*
425 1997;104(6):689-96.
- 426 39. Hladunewich MA, Derby GC, Lafayette RA, Blouch KL, Druzin ML, Myers BD.
427 Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized
428 controlled trial. *Obstet Gynecol.* 2006;107(4):886-95.
- 429 40. Roes EM, Raijmakers MT, Boo TM, Zusterzeel PL, Merkus HM, Peters WH,
430 et al. Oral N-acetylcysteine administration does not stabilise the process of
431 established severe preeclampsia. *Eur J Obstet Gynecol Reprod Biol.*
432 2006;127(1):61-7.
- 433 41. Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M, Volpe A. L-arginine
434 supplementation in patients with gestational hypertension: a pilot study. *Hypertens*
435 *Pregnancy.* 2007;26(1):121-30.
- 436 42. Sanchez-Ramos L, Adair CD, Kaunitz AM, Briones DK, Del Valle GO, Delke I.
437 Calcium supplementation in mild preeclampsia remote from term: a randomized
438 double-blind clinical trial. *Obstet Gynecol.* 1995;85(6):915-8.

- 439 43. Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henriksen T. Dietary
440 supplementation with L-arginine or placebo in women with pre-eclampsia. *Acta*
441 *Obstet Gynecol Scand*. 2004;83(1):103-7.
- 442 44. Collaborative Low-dose Aspirin Study in Pregnancy Collaborative (CLASP)
443 Group. A randomised trial of low-dose aspirin for the prevention and treatment of
444 pre-eclampsia among 9364 pregnant women. *Lancet*. 1994;343(8898):619-29.
- 445 45. Ganzevoort W, Rep A, Bonse GJ, Fetter WP, van Sonderen L, De Vries JI, et
446 al. A randomised controlled trial comparing two temporising management strategies,
447 one with and one without plasma volume expansion, for severe and early onset pre-
448 eclampsia. *BJOG*. 2005;112(10):1358-68.
- 449 46. Ginosar Y, Nadjari M, Hoffman A, Firman N, Davidson EM, Weiniger CF, et al.
450 Antepartum continuous epidural ropivacaine therapy reduces uterine artery vascular
451 resistance in pre-eclampsia: a randomized, dose-ranging, placebo-controlled study.
452 *Br J Anaesth*. 2009;102(3):369-78.
- 453 47. Hennessey MH, Rayburn WF, Stewart JD, Liles EC. Pre-eclampsia and
454 induction of labor: a randomized comparison of prostaglandin E2 as an intracervical
455 gel, with oxytocin immediately, or as a sustained-release vaginal insert. *Am J Obstet*
456 *Gynecol*. 1998;179(5):1204-9.
- 457 48. Vigil-De Gracia P, Reyes Tejada O, Calle Minaca A, Tellez G, Chon VY,
458 Herrarte E, et al. Expectant management of severe preeclampsia remote from term:
459 the MEXPRES Latin Study, a randomized, multicenter clinical trial. *Am J Obstet*
460 *Gynecol*. 2013;209(5):425.e1-8.
- 461 49. Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS, et al.
462 Variation in outcome reporting in endometriosis trials: a systematic review. *American*
463 *Journal of Obstetrics & Gynecology*. 214(4):452-64.

464 50. Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS, et al.
465 Variation in Outcome Reporting in Endometriosis Trials: A Systematic Review.
466 Obstetrical & Gynecological Survey. 2016;71(9):521-2.

467 51. Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, et al.
468 Strategy for standardization of preeclampsia research study design. Hypertension
469 (Dallas, Tex : 1979). 2014;63(6):1293-301.

470 52. Khan K. The CROWN Initiative: journal editors invite researchers to develop
471 core outcomes in women's health. BJOG. 2014;121(10):1181-2.

472 53. Duffy JMN, Bhattacharya S, Herman M, Mol B, Vail A, Wilkinson J, et al.
473 Reducing research waste in benign gynaecology and fertility research. BJOG: An
474 International Journal of Obstetrics & Gynaecology. 2017;124(3):366-9.

475 54. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et
476 al. Developing core outcome sets for clinical trials: issues to consider. Trials.
477 2012;13:132.

478 55. Hirsch M, Duffy JMN, Barker C, Hummelshoj L, Johnson NP, Mol B, et al.
479 Protocol for developing, disseminating and implementing a core outcome set for
480 endometriosis. BMJ Open. 2016;6(12).

481 56. Whitehouse KC, Kim CR, Ganatra B, Duffy JMN, Blum J, Brahmi D, et al.
482 Standardizing abortion research outcomes (STAR): a protocol for developing,
483 disseminating and implementing a core outcome set for medical and surgical
484 abortion. Contraception.

485 57. van 't Hooft J, Duffy JM, Daly M, Williamson PR, Meher S, Thom E, et al. A
486 Core Outcome Set for Evaluation of Interventions to Prevent Preterm Birth. Obstet
487 Gynecol. 2016;127(1):49-58.

488 58. Duffy J, van 't Hooft J, Gale C, Brown M, Grobman W, Fitzpatrick R, et al.
489 JP228 A pre-eclampsia core outcome set developed by 283 healthcare
490 professionals, 41 researchers, and 112 patients from 55 countries. BJOG: An
491 International Journal of Obstetrics & Gynaecology. 2017;124(S1):151-2.

492